{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:56:00Z","timestamp":1791262560260,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404074"],"award-info":[{"award-number":["82404074"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endocrine therapy with CDK4\/6 inhibitor has been the main treatment for HR+\/HER2\u2212 breast cancer in the adjuvant setting; however, the data on the application in the neoadjuvant setting is limited. We compared neoadjuvant efficacy and safety of sequential chemotherapy\u2010CDK4\/6 inhibitors with chemotherapy alone in HR+\/HER2\u2212 breast cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Female patients with HR+\/HER2\u2212 breast cancer who received neoadjuvant therapy at the Fifth Medical Center of the PLA General Hospital from November 2019 to March 2025 were enrolled. The objective response rate (ORR), pathological complete response (pCR), and event\u2010free survival (EFS) between the two treatment groups were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 181 enrolled patients, 142 received chemotherapy alone (NCT cohort) and 39 received CDK4\/6 inhibitors plus endocrine therapy (NCT\u2010ET cohort) after chemotherapy as preoperative therapy. Overall pCR was similar across cohorts (3.5% in NCT cohort vs. 2.6% in NCT\u2010ET cohort,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20091.000), as was ORR (72.5% vs. 69.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.685). The 3\u2010year EFS rate was numerically higher in the NCT\u2010ET cohort (96.7% vs. 83.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.111). However, among patients who failed to achieve partial response (PR) within 4\u2009cycles of chemotherapy, switching to endocrine therapy was associated with improved ORR (61.3% vs. 30.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). Overall pCR (3.2% vs. 0.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.356) and 3\u2010year EFS rate (95.7% vs. 78.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.105) were numerically higher in the NCT\u2010ET cohort. The total incidence of grade \u2265\u20093 adverse effects was higher in the NCT\u2010ET cohort (69.2% vs. 47.8%). However, for patient received endocrine therapy after chemotherapy, grade \u2265\u20093 events decreased from 66.7% during chemotherapy phase to 20.5% after switching to endocrine therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite no statistically significant differences in observed overall pCR and 3y\u2010EFS between patients treated with NCT or NCT\u2010ET, the sequential endocrine strategy was associated with improved ORR among patients who did not achieve PR after four cycles of chemotherapy and a lower incidence of adverse events during endocrine therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.72258","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:37:41Z","timestamp":1788838661000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Neoadjuvant Chemotherapy Followed by\n                    <scp>CDK4<\/scp>\n                    \/6 Inhibitors Plus Endocrine Therapy in Patients With\n                    <scp>HR<\/scp>\n                    \u2010Positive,\n                    <scp>HER2<\/scp>\n                    \u2010Negative Breast Cancer: A Retrospective Single\u2010Centre Cohort Analysis"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9085-8622","authenticated-orcid":false,"given":"Xiaopei","family":"Dong","sequence":"first","affiliation":[{"name":"Senior Department of Oncology Medicine Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3530-0487","authenticated-orcid":false,"given":"Fan","family":"Li","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology Medicine Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology Medicine Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Song","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology Medicine Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhe","family":"Wang","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology Medicine Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hao","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology Medicine Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinping","family":"Dong","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology Medicine Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology Medicine Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Bian","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology Medicine Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology Medicine Chinese PLA General Hospital  Beijing China"},{"name":"Department of Oncology The Second Affiliated Hospital of Anhui Medical University  Hefei Anhui Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-0452","authenticated-orcid":false,"given":"Jianbin","family":"Li","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology Medicine Chinese PLA General Hospital  Beijing China"},{"name":"Department of Medical Molecular Biology Beijing Institute of Biotechnology, Academy of Military Medical Sciences  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep44673"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00581-3"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3492"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-11223-3"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298928"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01064"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.02.009"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22789"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1897"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.21.1627"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.6187"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.015"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.515"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00907-2"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03197-w"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00435"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1010"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234191"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2203485"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035928"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.72258","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:47:11Z","timestamp":1791262031000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.72258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/cam4.72258"],"URL":"https:\/\/doi.org\/10.1002\/cam4.72258","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72258"}}